On April 1st the experts issued a rebuttal letterto the EMA, following the regulator’s dismissal of their earlier warnings regarding COVID-19 vaccine dangers from clotting and bleeding.
Within days of the EMA receiving the group’s original letter on March 1st, outlining risks of blood disorders from COVID-19 vaccines, over a dozen countries suspended the AstraZeneca vaccine following deaths from clotting and bleeding, as the doctors had warned.
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein.
When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.
Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.
We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.